4Ngwuluka N, Pillay V, Du Toit LC, et al. Levodopa delivery systems advancements in delivery of the gold standard [ J ]. Expert Opin Drag Deliv ,2010,7 (2) : 203 - 224.
5Pezzoli C, Zini M. Levodopa in Parkinson's disease :from the past to the future [ J ]. Expert Opin Pharmacother, 2010, 11 (4) :627 -635.
6Lebrun FC, Bowg M. Choosing the right dopamine agonist for patients with Parkinson's disease [ J]. Currmrd Res Opin, 2002,18 (4) :209 - 214.
7Maggio R, Scarmelli M, Novi F, et al. Potent activation of dopamine D2/D3 heterodimers by the antiparkingonian a- gents pramipexole and ropiniyole [ J ]. J Neurochem, 2001, 87(3) :631 -641.
8Eisenreieh W, Sommer B, Hartter S, et al. Pramipexole ex-tended release: a novel treatment option in Parkinson's dis- ease [ J]. Parkinsons Dis,2010,19:612 - 619.
9Asanuma M, Miyazaki L, Diaz-Corrales FJ, et al. Prami- pexole has ameliorating effects on levodopa-induced abnor- mal dopamine turnover inparkinsonian stratum and quench- ing effects on dopamine-semiquinnone generated in vitro [ J]. Neurol Res ,2005,27 (2) :533 - 539.
10Ives N J, Stowe RL, Mayyo J, et al. Monoamine oxidase type B inhibitors in early Parkinson's disease:meta-analysis of 17 randomised trials involving 3,525 patients [ J ]. BMJ, 2004, 329(7466) :593.
